LEXARIA BIOSCIENCE CORP. financials

LEXX CIK 0001348362

Source: EDGAR filings · Built 2026-06-19T01:10:14Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -10.48M -5.00M -5.91M -4.97M -2.62M
EBITDA -11.83M -5.71M -6.39M -6.52M -5.58M
Working Capital 1.97M 6.80M 1.88M 6.78M 12.29M 1.70M
Net Debt -1.69M -6.23M -1.02M -5.76M -10.79M -1.26M
Gross Margin 99.61% 98.96% 86.07% 71.87% 75.74% 56.02%
Operating Margin -1683.01% -1239.16% -2888.50% -2591.67% -786.85%
Net Margin -1686.00% -1248.25% -2946.36% -2846.28% -557.19% -1062.20%
Return on Equity (ROE) -398.10% -72.11% -218.94% -91.45% -30.83% -164.55%
Return on Assets (ROA) -285.07% -65.35% -216.11% -92.79% -30.35% -144.42%
Current Ratio 2.32× 7.18× 8.03× 35.96× 81.18× 8.53×
Debt-to-Equity 0.04× 0.03× 0.11× 0.01× 0.01× 0.01×
Effective Tax Rate 0.00% -0.15% -0.06%
Cash Conversion Ratio 0.88× 0.86× 0.88× 0.67× 0.99× 0.64×
Accruals Ratio -0.35× -0.09× -0.25× -0.31× -0.00× -0.52×
SBC % of Revenue 121.75% 106.02% 75.32% 294.68% 56.73% 296.27%
CapEx Coverage -424.02× -115.29× -174.27× -52.02×
Free Cash Flow Per Share $-0.58 $-0.40 $-0.89 $-0.94

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 464.28K 226.21K 255.40K 722.74K 384.54K
Revenues 705.92K 464.28K 226.21K 255.40K 722.74K 314.79K
Cost of Goods and Services Sold 2.72K 4.82K 31.50K 71.84K 175.35K 99.38K
Gross Profit 703.20K 459.46K 194.71K 183.56K 547.39K 215.41K
Research and Development Expense 8.24M 2.36M 3.67M 1.84M 1.26M 387.07K
Operating Expenses 12.58M 6.21M 6.73M 6.80M 6.23M 4.36M
Operating Income (Loss) -11.88M -5.75M -6.53M -6.62M -5.69M
Income Tax Expense (Benefit) 0 6.09K 2.32K
Net Income (Loss) Attributable to Parent -11.90M -5.80M -6.66M -7.27M -4.03M -4.08M
Earnings Per Share, Diluted $-0.66 $-0.47 $-1.01
Weighted Average Number of Shares Outstanding, Diluted 18.00M 12.38M 6.61M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 5.81M 10.92M 1.29M
Assets, Current 3.47M 7.90M 2.15M 6.98M 12.44M 1.93M
Assets 4.18M 8.87M 3.08M 7.83M 13.27M 2.83M
Liabilities, Current 1.49M 1.10M 267.74K 194.04K 153.28K 225.92K
Liabilities 1.57M 1.21M 403.91K 201.44K 203.26K 345.98K
Stockholders' Equity Attributable to Parent 2.99M 8.04M 3.04M 7.95M 13.06M 2.48M
Common Stock, Shares, Outstanding 19.56M 19.56M 8.09M 5.95M 5.73M 3.00M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -10.45M -4.96M -5.88M -4.88M -3.99M -2.62M
Payments to Acquire Property, Plant, and Equipment 24.65K 43.01K 33.75K 49.19K 0
Net Cash Provided by (Used in) Investing Activities -243.02K -188.60K -169.61K -180.64K 193.88K -26.84K
Net Cash Provided by (Used in) Financing Activities 6.05M 10.32M 1.59M -44.60K 13.42M 2.65M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (LEXX CIK 0001348362), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

BOLT

Bolt Biotherapeutics, Inc.

IVDA

IVEDA SOLUTIONS, INC.

SII

Sprott Inc.